Number Of Approved Bispecific Antibodies Is Expected To Surpass 16 Bispecific Antibodies By 2029 Says Kuick Research
Delhi, March 17, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights:
-
Global Market Forecast Till 2029: > USD 36 Billion
-
Approved Bispecific Antibodies: 11
-
Yearly & Quarterly Sales Insight
-
Global & Regional Sales Insights
-
Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
-
Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
-
Fast Track Approval, Orphan Designation & Priority Status Insights
-
Approved Bispecific Antibodies Pricing & Dosage Analysis
-
Top 30 Companies Developing Bispecific Antibodies Competitive Insight
-
800 Pages Clinical & Commercial Opportunity insight
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market
Xencor's plamotamab represents a novel bispecific monoclonal antibody therapeutic candidate engineered to harness the immune system's antitumor potential. This innovative molecule incorporates an Fc domain and exhibits dual antigen-binding specificity, a design strategy that confers it with prospective anti-cancer activity. One of plamotamab's antigen-binding domains is directed against human CD3, a surface antigen expressed on T lymphocytes, while the other domain selectively recognizes and binds to human CD20, a tumor-associated antigen predominantly overexpressed on B cells across various developmental stages. Xencor has signed an exclusive collaboration and worldwide license agreement with Janssen Biotech for the development and commercialization of plamotamab.
The XmAb® Bispecific Fc Domain, a proprietary platform developed by Xencor, serves as the molecular scaffold underpinning plamotamab's unique bifunctional design. This engineered Fc region not only enables the integration of the two distinct antigen-binding domains but also confers favorable pharmacokinetic properties on the antibody, including an extended circulating half-life, enhanced stability, and streamlined manufacturing processes. Upon systemic administration, plamotamab simultaneously engages with both T lymphocytes, via the CD3-targeting arm, and malignant B-lineage cells overexpressing the CD20 tumor-associated antigen.
This dual binding event initiates a potent antitumor immune response, wherein plamotamab facilitates the recruitment and activation of cytotoxic T cells against the CD20-positive cancer cell population. Notably, the presence of the Fc domain within plamotamab's structure not only contributes to its prolonged persistence in circulation but also augments the T-cell-mediated cytotoxicity against tumor cells. This is achieved through Fc receptor binding, which potentiates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), further amplifying the destruction of malignant B cells.